XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
  Anti-Inflammatory
  Antivirals
  Antihypertensives
  Anticholesterol
  Anti-Clotting Drugs
  Anti Cancer Drugs
  Hypnotics
  PPI
  Antibiotics
  Analgesics
  Surfactants
  Fatty Acids
  Adrenergics
  Metals
  Varenicline
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Pharmacology Channel
subscribe to Pharmacology newsletter

Latest Research : Pharmacology

   DISCUSS   |   EMAIL   |   PRINT
FDA Approves High Dose Kadian(R) for Severe Chronic Pain
May 6, 2005, 10:13, Reviewed by: Dr.

"Kadian(R) already has a significant advantage over competitive products as a result of the dosing flexibility it offers physicians and their patients and is the only brand in its category that can be dosed either once or twice daily. This added dosage form, which will be marketed by our recently expanded sales force, will help physicians individualize their patients treatments by offering more choices in managing their pain."

 
Alpharma Inc. (NYSE: ALO),a leading global generic pharmaceutical company, today announced that it has been notified by United States Food and Drug Administration that its pending application for Kadian(R) 200mg capsule has received approvable status.

Kadian(R) is Alpharma's branded sustained release morphine sulfate product and is currently marketed in 20mg, 30mg, 50mg, 60mg and 100mg dosages. The company plans to launch the new dosage form following final FDA approval.

"We are extremely pleased to receive approvable status on this important new higher dosage of Kadian(R) which will help meet the needs of some the most severe sufferers of chronic pain," commented Ronald Warner, PhD, President of
Alpharma's Branded Products business. "Kadian(R) already has a significant advantage over competitive products as a result of the dosing flexibility it offers physicians and their patients and is the only brand in its category
that can be dosed either once or twice daily. This added dosage form, which will be marketed by our recently expanded sales force, will help physicians individualize their patients treatments by offering more choices in managing their pain."
 

- U.S. Food and Drug Administration (FDA)
 

www.alpharma.com

 
Subscribe to Pharmacology Newsletter
E-mail Address:

 

Alpharma Inc. (NYSE: ALO) is a global generic pharmaceutical company with leadership positions in products for humans and animals. Uniquely positioned to expand internationally, Alpharma is presently active in more than 60 countries. Alpharma is a leading manufacturer of generic pharmaceutical products in the U.S., offering solid, liquid and topical pharmaceuticals. It is also one of the largest suppliers of generic solid dose pharmaceuticals in Europe, with a growing presence in Southeast Asia. Alpharma is among the worlds leading producers of several important pharmaceutical-grade bulk
antibiotics and is internationally recognized as a leading provider of pharmaceutical products for poultry, swine and cattle.


Related Pharmacology News

Phase Ib Trial Is Evaluating Bavituximab Administered With Common Chemotherapy Regimens
Two-component lantibiotic with therapeutic potential discovered
Prescription pain medication abuse on rise
Antibiotic inhibits cancer gene activity
NRTIs limits the atherogenic side effect of the protease inhibitors
Cyclin-dependent kinase inhibitors: The latest anti-inflammatory
FDA requested to promptly approve 17-P to prevent premature birth
Rapamycin shown to inhibit angiogenesis
Tigecycline, world�s first glycylcycline expanded broad-spectrum antibiotic, launched in UK
Ibuprofen - worsening cognitive function


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us